Showing results (311-320 of 444) with videos related to

Sort By:
Pageof 45
ERJ Open Research|January 21, 2026
Cost-effectiveness of as-needed budesonide-formoterol in adults with mild asthma: the Novel START trialWilliam Leung, Helen K Reddel, Tiffany Hung, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 28, 2025
Targeted Treatment in Asthma-Opportunities and ChallengesIoana Agache, Magdalena Zemelka-Wiacek, Radosław Gawlik, et al.
Plos One|March 12, 2015
Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trialAlessia Verduri, Fabrizio Luppi, Roberto D'Amico, et al.
The Journal of Allergy and Clinical Immunology|November 16, 2025
Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthmaIan D Pavord, Njira L Lugogo, Mario Castro, et al.
The Lancet. Respiratory Medicine|March 17, 2019
Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort studyDirkje S Postma, Chris Brightling, Simonetta Baldi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 5, 2008
Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 productionSimon D Message, Vasile Laza-Stanca, Patrick Mallia, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|April 7, 2016
The management of asthma in the phenotype and biomarker era: The proposal of a new diagnostic-therapeutic modelFrancesco Blasi, Germano Bettoncelli, Giorgio Walter Canonica, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 27, 2016
Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group InitiativeJohn D Blakey, David B Price, Emilio Pizzichini, et al.
Allergy|August 17, 2021
From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseasesIan D Pavord, Elisabeth H Bel, Arnaud Bourdin, et al.
Allergy|July 11, 2023
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids doseIan D Pavord, Arnaud Bourdin, Alberto Papi, et al.
Pageof 45